Zealand Pharma A/S
  • About Zealand
    • About Us
    • Disease Spotlights
    • History
    • Corporate Management
    • Corporate Governance
    • Corporate Social Responsibility
    • Board of Directors
    • Videos About Zealand
    • Transparency Reporting
  • R&D
    • Our Focus
    • Product Pipeline
    • Glepaglutide for SBS
    • Dasiglucagon for CHI
    • Survodutide (BI 456906) GLP-1/Glucagon Dual Agonist
    • ZP8396 (Amylin Analog)
    • Dapiglutide (GLP-1/GLP-2 Dual Agonist)
    • Dasiglucagon for BHAP Systems
    • Partnering and In-licensing
    • What are Peptides?
    • Peptide Platform Video
  • Investor
    • Investor Relations
    • Corporate Presentation
    • Stock Information
    • Shareholder Portal
    • Financial Calendar
    • Financial Reports
    • Events
    • Annual General Meeting
    • SEC Filings
    • Analyst Coverage
    • Prospectus
  • Media
    • Zealand News
    • Media Inquiry
    • Downloads
  • Careers
    • Zealand as a Workplace
    • Meet Us
    • Positions
    • Personal Data in the Recruitment Process
    • Disclaimer: Beware of Recruitment Fraud
  • Contact
  • Financial Reports
  • Financial Reports for 2022
  • Financial Reports for 2021
  • Financial Reports for 2020
  • Financial Reports for 2019
  • Financial Reports for 2018
  • Financial Reports for 2017
  • Financial Reports for 2016
  • Financial Reports for 2015
  • Financial Reports for 2014

Financial reports for 2022

Annual Report

Interim Report for Q3 2022

Interim Report for H1 2022

Interim report for Q1 2022

Zealand Pharma A/S     Sydmarken 11      2860 Søborg Denmark     Tel +45 88 77 36 00     info@zealandpharma.com

Legal disclaimer     Privacy policy